EC Use in Australia (2004)

Australia House of Representative Notice Paper[to Australia Health Minister Tony Abbott, 2June04, with questions about levonorgestrel MAP]*3613 MR MURPHY: To ask the Minister for Health and Ageing —(1) In respect of the sale without prescription of the drug Postinor-2, which contains the active ingredient levonorgestrol, is he aware of the article titled “Adverse reactions and emergency contraception” in The Lancet on 14 April 2001, which states that (a) several writers in the United Kingdom have remarked on the scarcity of safety data regarding the adverse reactions from use of the drug levonorgestrel, (b) 5% of women have a genetic susceptibility to breast and ovarian cancer and another 5% have a genetic susceptibility to thromoembolic disease, and (c) the relevant tests will not generally be done before a pharmacist supplies levonorgestrel to women who may have stopped taking daily hormones because they had adverse reactions. (2) Can he explain how the women who take levonorgestrel without prescription will be protected against the potential side-effects of the drug. (3)  Is he able to say what scientific evidence his department relies on when deciding on the sale without prescription of products containing levonorgestrel; if not, when will he require the withdrawal from sale of Postinor-2 and, if he will not, why not. (4) Can he explain how the precautionary principle applies to the supply without prescription of levonorgestrel to women; if not, why not. *3614 MR MURPHY: To ask the Minister for Health and Ageing —(1) In respect of the sale without prescription of the drug Postinor-2, which contains the active ingredient levonorgestrel, is he aware of the article by Professor Richards...